Compare CELU & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELU | KYNB |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5M | 31.9M |
| IPO Year | N/A | N/A |
| Metric | CELU | KYNB |
|---|---|---|
| Price | $1.28 | $7.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 31.7K | 30.9K |
| Earning Date | 11-14-2025 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | ★ $40,578,000.00 | $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.00 | N/A |
| P/E Ratio | ★ N/A | $0.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $4.85 |
| 52 Week High | $4.35 | $21.94 |
| Indicator | CELU | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 36.71 |
| Support Level | $1.20 | $7.32 |
| Resistance Level | $1.31 | $8.25 |
| Average True Range (ATR) | 0.07 | 0.67 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 68.75 | 15.80 |
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.